Moneycontrol PRO
you are here: HomeNewsTrendsHealth

Current COVID-19 vaccines may be less effective against Beta variant: Study

Present on the surface of SARS-COV-2, spike proteins enable the virus to attach to and enter our cells, and all current vaccines are directed against them.

June 28, 2021 / 01:23 PM IST
Representative image

Representative image

A study of the spike protein of SARS-CoV-2, the virus which cause COVID-19, suggests that current vaccines may be less effective against the Beta variant first identified in South Africa.

Present on the surface of SARS-COV-2, spike proteins enable the virus to attach to and enter our cells, and all current vaccines are directed against them.

The study, published in the journal Science on June 24, used cryo-electron microscopy (cryo-EM) to compare the spike protein from the original virus found in China in 2019, with that of the Beta variant, and the Alpha variant first identified in the UK.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

Cryo-Em is an imaging technique used to determine the biomolecular structures at near-atomic resolution.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

The findings led by researchers at Boston Children's Hospital in the US indicate that mutations in the Beta variant, also known as B.1.351, change the shape of the spike surface at certain locations.

As a result, neutralising antibodies induced by current vaccines are less able to bind to the Beta virus, which may allow it to evade the immune system even when people are vaccinated.

"The mutations make antibodies stimulated by the current vaccine less effective," said Bing Chen, from the division of Molecular Medicine at Boston Children's.

“The Beta variant is somewhat resistant to the current vaccines, and we think a booster with the new genetic sequence can be beneficial for protecting against this variant," Chen added.

The researchers also found that mutations in the Beta variant make the spike less effective in binding to ACE2 -- suggesting that this variant is less transmissible than the Alpha variant.

As for the Alpha variant (B.1.1.7), the study confirms that a genetic change in the spike helps the virus bind better to ACE2 receptors, making it more infectious.

However, testing indicates that antibodies elicited by existing vaccines can still neutralise this variant, according to the researchers.

They said to be a heightened threat, a SARS-CoV-2 variant would need to do three things: spread more easily, evade the immune system in vaccinated people or those previously exposed to COVID-19, and cause more severe disease.

However, the researchers said the Alpha and Beta variants do not meet all these criteria.

"Our data suggest that the most problematic combination of such mutations is not yet present in the existing variants examined here," they added.

The research team is now analysing the structures of other variants of concern, including the Delta variant (B.1.617.2), first identified in India.

Follow our full coverage of the coronavirus pandemic here.

first published: Jun 28, 2021 01:21 pm